Published on 20/06/2007 at 18:58
by rimonabantreport
Information about Diet Pill Rimonabant
No professional would tell you that diet pills are an ideal solution. However the stress that modern life puts us through means that they are sometimes a necessary last resort.
Information about Diet Pill Rimonabant
Doctors usually recommend that you take Rimonabant on an empty stomach, preferably an hour before meals. The pills must be taken whole or split in half - crushing or chewing can increase side effects and reduce Ionamin's long-lasting action. Only take as much as your doctor prescribes as there is a risk of overdose. Rimonabant should also not be taken in conjunction with other diet pills. If you miss a dose then do not double-dose the next day. A dose taken late in the day may also cause insomnia.
Information about Diet Pill Rimonabant
You should consult your doctor if you have any of the following conditions: Heart disease, Arteriosclerosis, Glaucoma, Thyroid problems, Anxiety, a seizure disorder such as epilepsy, Diabetes, a history of drug/alcohol abuse.
Published on 20/06/2007 at 16:23
by rimonabantreport
Rimonabant
Rimonabant is suitable for restricted prescribing in primary care; it should not be used routinely. Rimonabant should not be used in patients with psychiatric illness such as depression or in combination with antidepressants. Appropriate psychiatric asses sment should be considered before prescribing and during treatament with rimonabant
Rimonabant
It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
Rimonabant
Acomplia (rimonabant) has been available in Europe since the middle of 2006, following regulatory approval by the EMEA in June 2006 for its use as an adjunct to diet and exercise for obese or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaeamia. However, it has had a less easy passage through the US regulatory system.
